Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,112.20 -206.04 -1.35%
S&P 500 1,628.93 -22.88 -1.39%
Nasdaq 3,443.20 -38.98 -1.12%
Ticker Volume Price Price Delta
STOXX 50 2,683.98 -16.95 -0.63%
FTSE 100 6,348.82 -25.39 -0.40%
DAX 8,197.08 -32.43 -0.39%
Ticker Volume Price Price Delta
Nikkei 13,245.20 +237.94 1.83%
Hang Seng 20,986.90 -238.99 -1.13%
S&P/ASX 200 4,861.38 +47.03 0.98%
  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Novogen Ltd

+ Add to Watchlist

NVGN:US

4.0800 USD 0.0200 0.49%

As of 17:20:00 ET on 06/19/2013.

Company Profile for Novogen Ltd (NVGN)

Novogen Limited is a medical services company which develops and markets pharmaceutical products in Australia. The Company conducts clinical trials on medications which promote the prevention and treatment of common cancers and the reversal of immune depression. The Company also develops dietary supplements, hormonal imbalance drugs, anti-inflammatory and cardiovascular drugs.

Contact Information

Novogen Ltd

140 Wicks Road
North Ryde, NSW 2113
Australia
Phone: 61-2-9878-0088
Fax: 61-2-9878-0055

Key Executives for Novogen Ltd (NVGN)

Graham Edmund KellyChairman/CEO/FounderMark G HinzeChief Financial Officer
Andrew William BursillSecretary

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil